The availability of weight loss drugs on the NHS doesn’t mean people can give up healthy lifestyles, Health Secretary Wes ...

The co-founder of Regeneron has warned that blockbuster weight-loss drugs could cause “more harm ... is dominated by Ozempic and Wegovy maker Novo Nordisk and Eli Lilly, the company behind Mounjaro ...

A portfolio holding that checks all these boxes is analog chip maker Texas Instruments (TXN). The company invests to build out its own manufacturing capacity, which helps make it a low-cost supplier.

The San Francisco telehealth company had capitalized on the shortage by making copycat versions of popular brand-name GLP-1 ...

The FDA has resolved Eli Lilly's tirzepatide shortage, but localized supply issues persist. Meanwhile, Hims & Hers Health's ...

The two-year shortage of Eli Lilly’s blockbuster weight-loss and diabetes drugs is over, the U.S. Food and Drug ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 569.58% and ...

Newly released data shows that the U.S. may have reached peak obesity in 2020 — and the timing unsurprisingly coincides with ...

The FDA confirmed Thursday that Eli Lilly has increased production of its blockbuster weight-loss drug Zepbound and type 2 ...

The roadmap suggests those with the greatest clinical need will get priority access, according to the NHS national medical ...

NHS England plans a phased rollout of tirzepatide to treat severe obesity, with early trials showing significant weight loss.

Scaling GLP-1 manufacturing capacity remains a key priority for the pharma industry, to help supply catch up with the ...